451 related articles for article (PubMed ID: 29081841)
41. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
[TBL] [Abstract][Full Text] [Related]
42. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Boussios S; Moschetta M; Karihtala P; Samartzis EP; Sheriff M; Pappas-Gogos G; Ozturk MA; Uccello M; Karathanasi A; Tringos M; Rassy E; Pavlidis N
Ann Transl Med; 2020 Dec; 8(24):1706. PubMed ID: 33490218
[TBL] [Abstract][Full Text] [Related]
43. PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer.
Hirschl N; Leveque W; Granitto J; Sammarco V; Fontillas M; Penson RT
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473293
[TBL] [Abstract][Full Text] [Related]
44. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Boussios S; Karihtala P; Moschetta M; Karathanasi A; Sadauskaite A; Rassy E; Pavlidis N
Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31374917
[TBL] [Abstract][Full Text] [Related]
45. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
46. Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of
Wei Q; Chen DS; Liu YH
Front Oncol; 2022; 12():853211. PubMed ID: 35359396
[TBL] [Abstract][Full Text] [Related]
47. PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
Boussios S; Karathanasi A; Cooke D; Neille C; Sadauskaite A; Moschetta M; Zakynthinakis-Kyriakou N; Pavlidis N
Diagnostics (Basel); 2019 May; 9(2):. PubMed ID: 31109041
[TBL] [Abstract][Full Text] [Related]
48. Niraparib Slows Ovarian Cancer Progression.
Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
[TBL] [Abstract][Full Text] [Related]
49. Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic
Tao M; Cheng J; Wu X
Onco Targets Ther; 2020; 13():12979-12986. PubMed ID: 33376347
[TBL] [Abstract][Full Text] [Related]
50. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
[TBL] [Abstract][Full Text] [Related]
51. Niraparib-induced STAT3 inhibition increases its antitumor effects.
Zhao Q; Kohut A; Li YJ; Martincuks A; Austria T; Zhang C; Santiago NL; Borrero RM; Phan XT; Melstrom L; Rodriguez-Rodriguez L; Yu H
Front Oncol; 2022; 12():966492. PubMed ID: 36324587
[TBL] [Abstract][Full Text] [Related]
52. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
Jiang X; Li W; Li X; Bai H; Zhang Z
Cancer Manag Res; 2019; 11():4371-4390. PubMed ID: 31191001
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer.
Paik ES; Chang HK; Lee S
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370704
[TBL] [Abstract][Full Text] [Related]
54. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
Kaye SB
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i1-i3. PubMed ID: 27141062
[TBL] [Abstract][Full Text] [Related]
55. Niraparib - A promising drug with hematological toxicity.
Patibandla NS; Monga DK
J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
[TBL] [Abstract][Full Text] [Related]
56. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
Milanesio MC; Giordano S; Valabrega G
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455819
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Jang A; Sartor O; Barata PC; Paller CJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320
[TBL] [Abstract][Full Text] [Related]
58. Update on PARP1 inhibitors in ovarian cancer.
Sessa C
Ann Oncol; 2011 Dec; 22 Suppl 8():viii72-viii76. PubMed ID: 22180407
[TBL] [Abstract][Full Text] [Related]
59. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
60. Tailoring Ovarian Cancer Treatment: Implications of
Madariaga A; Lheureux S; Oza AM
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30909618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
